

1. Garton KJ, Ferri N, Raines EW. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. *Biotechniques*. 2002;32(4):830, 832, 834 passim.
2. Ferri N, Garton KJ, Raines EW. An NF-kappaB-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells. *J Biol Chem*. 2003;278(22):19757-19764.
3. Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangi leiomyomatosis. *Am J Pathol*. 2004;164(5):1575-1585.
4. Raines EW, Garton KJ, Ferri N. Beyond the endothelium: NF-kappaB regulation of smooth muscle function. *Circ Res*. 2004;94(6):706-708.
5. Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. *Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals*. 2005;10(4):219-237.
6. Raines EW, Ferri N. Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. *J Lipid Res*. 2005;46(6):1081-1092.
7. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? *Vasc Health Risk Manag*. 2007;3(5):611-613.
8. Ferri N, Colombo G, Ferrandi C, Raines EW, Levkau B, Corsini A. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. *Arterioscler Thromb Vasc Biol*. 2007;27(5):1043-1049.
9. Ferri N, Granata A, Pirola C, et al. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. *Molecular pharmacology*. 2008;74(1):144-153.
10. Baetta R, Granata A, Canavesi M, et al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. *The Journal of pharmacology and experimental therapeutics*. 2009;328(2):419-425.
11. Ferri N, Corsini A, Bottino P, Clerici F, Contini A. Virtual screening approach for the identification of new Rac1 inhibitors. *Journal of medicinal chemistry*. 2009;52(14):4087-4090.
12. Pirillo A, Reduzzi A, Ferri N, Kuhn H, Corsini A, Catapano AL. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. *Atherosclerosis*. 2011;214(2):331-337.
13. Ferri N. Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. *Scientifica*. 2012;2012:927352.
14. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. *Atherosclerosis*. 2012;220(2):381-386.
15. Greco CM, Camera M, Facchinetti L, et al. Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. *Cardiovascular research*. 2012;95(3):366-374.
16. Baetta R, Granata A, Miglietta D, et al. Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. *Cardiovasc Drugs Ther*. 2013;27(3):211-219.
17. Ferri N, Bernini SK, Corsini A, et al. 3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors. *Medchemcomm*. 2013;4(3):537-541.
18. Ferri N, Contini A, Bernini SK, Corsini A. Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors. *J Cardiovasc Pharmacol*. 2013;62(5):425-435.
19. Ferri N, Corsini A. Clinical evidence of statin therapy in non-dyslipidemic disorders. *Pharmacological research*. 2014;88:20-30.
20. Ruffoni A, Ferri N, Bernini SK, et al. 2-Amino-3-(phenylsulfanyl)norborene-2-carboxylate: an appealing scaffold for the design of Rac1-Tiam1 protein-protein interaction inhibitors. *Journal of medicinal chemistry*. 2014;57(7):2953-2962.

21. Brambilla M, Facchinetti L, Canzano P, et al. Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. *Thromb Haemost.* 2015;114(3):579-592.
22. Ferri N, Panariti F, Ricci C, Maiocchi G, Corsini A. Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. *Journal of the renin-angiotensin-aldosterone system : JRAAS.* 2015;16(2):284-291.
23. Adorni MP, Cipollari E, Favari E, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. *Atherosclerosis.* 2016;256:1-6.
24. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. *Pharmacological research.* 2016;111:592-599.
25. Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. *Translational research : the journal of laboratory and clinical medicine.* 2016;173:19-29.
26. Ferri N, Marchiano S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. *Atherosclerosis.* 2016;253:214-224.
27. Ferri N, Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. *Endocrine.* 2016;54(3):588-601.
28. Ruscica M, Ferri N, Macchi C, et al. Liver fat accumulation is associated with circulating PCSK9. *Annals of medicine.* 2016;48(5):384-391.
29. Ruscica M, Ricci C, Macchi C, et al. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. *J Biol Chem.* 2016;291(7):3508-3519.
30. Adorni MP, Ferri N, Marchiano S, et al. Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. *Therapeutics and clinical risk management.* 2017;13:1555-1562.
31. Contini A, Ferri N, Bucci R, et al. Peptide modulators of Rac1/Tiam1 protein-protein interaction: An alternative approach for cardiovascular diseases. *Biopolymers.* 2017.
32. Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings. *Expert opinion on investigational drugs.* 2017;26(5):593-602.
33. Ferri N, Corsini A, Sirtori CR, Ruscica M. Bococizumab for the treatment of hypercholesterolaemia. *Expert opinion on biological therapy.* 2017;17(7):909-910.
34. Ferri N, Marchiano S, Lupo MG, et al. Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. *Pharmacological research.* 2017;122:96-104.
35. Rimoldi I, Facchetti G, Lucchini G, Castiglioni E, Marchiano S, Ferri N. In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. *Bioorganic & medicinal chemistry.* 2017;25(6):1907-1913.
36. Ruscica M, Ferri N, Fogacci F, et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. *Journal of the American Heart Association.* 2017;6(5).
37. Zimetti F, Caffarra P, Ronda N, et al. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD.* 2017;55(1):315-320.
38. Camera M, Rossetti L, Barbieri SS, et al. PCSK9 as a Positive Modulator of Platelet Activation. *J Am Coll Cardiol.* 2018;71(8):952-954.
39. Ferri N, Corsini A, Sirtori CR, Ruscica M. Present therapeutic role of cholesteryl ester transfer protein inhibitors. *Pharmacological research.* 2018;128:29-41.
40. Lupo MG, Ferri N. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. *Journal of cardiovascular development and disease.* 2018;5(3).
41. Poggio P, Songia P, Cavallotti L, et al. PCSK9 Involvement in Aortic Valve Calcification. *J Am Coll Cardiol.* 2018;72(24):3225-3227.
42. Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. *Scientific reports.* 2018;8(1):2267.
43. Ruscica M, Ferri N, Corsini A, Sirtori CR. PCSK9 antagonists and inflammation. *Atherosclerosis.* 2018;268:235-236.

44. Ruscica M, Ferri N, Macchi C, Corsini A, Sirtori CR. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? *Annals of medicine*. 2018;50(6):461-484.
45. Ruscica M, Simonelli S, Botta M, et al. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. *Biochimica et biophysica acta Molecular and cell biology of lipids*. 2018;1863(9):991-997.
46. Zenti MG, Altomari A, Lupo MG, et al. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. *European journal of preventive cardiology*. 2018;25(17):1843-1851.
47. Adorni MP, Ruscica M, Ferri N, Bernini F, Zimetti F. Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. *Front Aging Neurosci*. 2019;11:120.
48. Dongiovanni P, Meroni M, Baselli G, et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. *J Lipid Res*. 2019;60(6):1144-1153.
49. Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Drugs*. 2019;79(7):751-766.
50. Lupo MG, Macchi C, Marchiano S, et al. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2019.
51. Macchi C, Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica M. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. *European journal of preventive cardiology*. 2019;26(9):930-949.
52. Macchi C, Ferri N, Favero C, et al. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. *European journal of preventive cardiology*. 2019;26(6):578-588.
53. Ruscica M, Macchi C, Fogacci F, et al. Angiotensin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. *European journal of preventive cardiology*. 2019;2047487319884378.
54. Wagner C, Green MFB, Maiworm M, et al. Quantitative imaging of electric surface potentials with single-atom sensitivity. *Nature materials*. 2019;18(8):853-859.
55. Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N. Naturally Occurring PCSK9 Inhibitors. *Nutrients*. 2020;12(5).
56. Ferri N, Corsini A. Clinical Pharmacology of Statins: an Update. *Current atherosclerosis reports*. 2020;22(7):26.
57. Ferri N, Ruscica M, Coggi D, et al. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. *Atherosclerosis*. 2020;309:39-46.
58. Lupo MG, Biancorosso N, Brilli E, et al. Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. *Nutrients*. 2020;12(2).
59. Macchi C, Favero C, Ceresa A, et al. Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance. *Cardiovascular diabetology*. 2020;19(1):187.
60. Macchi C, Greco MF, Botta M, et al. Leptin, Resistin, and Pcsk9 - the Role of Stat3. *Am J Pathol*. 2020.
61. Ruscica M, Corsini A, Ferri N, Banach M, Sirtori CR. Clinical approach to the inflammatory etiology of cardiovascular diseases. *Pharmacological research*. 2020;159:104916.
62. Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. *Pharmacological research*. 2020;153:104653.
63. Donato M, Faggin E, Cinetto F, et al. The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies. *Nutrients*. 2021;13(8).

64. Lupo MG, Arcidiacono D, Zaramella A, et al. Lomitapide does not alter PCSK9 1 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile. *Atherosclerosis Plus*. 2021;1(1).
65. Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M. Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact. *Am J Pathol*. 2021;191(8):1385-1397.
66. Rossato MS, Brilli E, Ferri N, Giordano G, Tarantino G. Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress. *Clin Nutr ESPEN*. 2021;46:510-518.
67. Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid Lowering Drugs: Present Status and Future Developments. *Current atherosclerosis reports*. 2021;23(5):17.
68. Ruscica M, Penson PE, Ferri N, et al. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). *Progress in cardiovascular diseases*. 2021;67:40-52.
69. Ruscica M, Sirtori CR, Ferri N, Corsini A. New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran. *Eur Heart J Suppl*. 2021;23(Suppl E):E59-E62.
70. Sut S, Ferrarese I, Lupo MG, et al. The Modulation of PCSK9 and LDLR by Supercritical CO₂ Extracts of *Mentha longifolia* and Isolated Piperitone Oxide, an In Vitro Study. *Molecules*. 2021;26(13).
71. Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. *Pharmacological research*. 2022;184:106439.
72. Lupo MG, Bressan A, Donato M, et al. PCSK9 promotes arterial medial calcification. *Atherosclerosis*. 2022;346:86-97.
73. Lupo MG, Brilli E, De Vito V, et al. In Vitro and In Vivo Sucrosomial((R)) Berberine Activity on Insulin Resistance. *Nutrients*. 2022;14(17).
74. Maharjan B, Payne DT, Ferrarese I, et al. Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. *Bioorganic Chemistry*. 2022;121.
75. Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. *Cardiovascular research*. 2023;118(17):3288-3304.